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Since the early 1990s, cellular cardiomyoplasty (or simply
cell transplantation) has been explored as a potential new
therapy to alleviate the consequences of myocardial infarc-
tion (MI) (1). Many different cell types have been tried (2)
and, quite naturally, cardiomyocytes were chosen early on,
reasoning that they would be the ideal replacement for lost
cardiomyocytes (3,4). Since these groundbreaking studies,
several investigators have shown that cardiomyocytes can
form viable grafts in and integrate with the host myocar-
dium (5–8). However, there are several significant draw-
backs to this cell type. The first problem stems from
availability, that is, for today’s infarct patient and likely for
the next several years, there is no feasible source of cardio-
myocytes for clinical applications. Embryonic stem cells
show the most promise for large scale cardiomyocyte pro-
duction, but much basic research remains to be done with
these cells before they could be used safely or effectively.
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The ethics of embryonic stem cell use are also being debated
in multiple arenas, indicating it will be some years before
these cells can be used for treating patients. Adult stem cells
(such as hematopoietic stem cells) circumvent the ethical
constraints of embryonic stem cells, but their more limited
plasticity makes generation of cardiomyocytes a very ineffi-
cient process at present. The second problem with cardio-
myocytes is that they are not a very hardy cell type.
Cardiomyocytes are quite ischemia-sensitive and die in large
numbers (up to 99%) after being grafted into a hostile
environment such as a healing infarct or an old scar (7,9).
Thus, while one can make new myocardium by cardiomy-
ocyte transplantation, it is very difficult to create it in
physiologically relevant amounts.
Skeletal muscle transplantation for cardiac repair. A way
out of this dilemma was shown with the use of stem cells
from skeletal muscle, so-called myoblasts or satellite cells.
Skeletal myoblasts are the mononucleated precursors to
skeletal myofibers, and, after injury, these normally quies-
cent cells proliferate and then fuse to regenerate new
multinucleated myofibers. The great advantage of using
myoblasts lies in the fact that these cells can be isolated from
the patient’s own skeletal muscle, expanded in vitro, and
transplanted back into the patient’s heart, thus circumvent-
ing any histocompatibility and/or ethical concerns involved
with the use of some other candidate cell types. In 1996, our
group found that skeletal myoblasts not only survived after
grafting into an injured heart, but also proliferated for
several days and then differentiated into mature myofibers
(10). Because of their increased survival and proliferative
capacity, much bigger grafts of skeletal muscle can be
generated by cell implantation. Phenotypically, the myofi-
bers were similar to fast-twitch skeletal muscle, but as
wound healing progressed, some fibers developed character-
istics of slow twitch muscle, for example, expression of slow
beta-myosin heavy chain. Fiber conversion was interpreted
as potentially beneficial to the heart because slow fibers are
much more fatigue-resistant and, thus, more suitable to
sustain a cardiac-type workload. Interestingly, there was also
some evidence for the establishment of a new satellite cell,
that is, stem-cell population. Skeletal muscle grafts in the
heart will contract when exogenously stimulated (10). How-
ever, they do not form electromechanical junctions with
cardiomyocytes due to the absence of intercalated disk
proteins (11). Thus, it is not clear whether skeletal muscle
grafts actually beat in vivo. This question remains one of the
major goals for basic scientists to answer.
Altogether, over 45 papers investigating skeletal myoblast
grafting for cardiac repair in various small and large animal
models have been published. Although space limitations
preclude a detailed review of their results, a few deserve
special attention. Considerable excitement resulted from the
work of Taylor et al. (12) who, for the first time, demon-
strated that autologous skeletal myoblast grafting into cryo-
injured rabbit hearts improved regional myocardial perfor-
mance in vivo. Then, in 2001, Jain et al. (13) found evidence
that syngeneic myoblast implantation after MI improves
both in vivo and ex vivo indexes of global ventricular
dysfunction after MI. Although infarct sizes were compa-
rable in the two groups, hearts with skeletal myoblast grafts
had significantly less ventricular remodeling. Thus, preven-
tion of remodeling is one potential mechanism by which
myoblast grafting can improve function of the infarcted
heart.
Skeletal muscle cell grafting for cardiac repair appears to
have come of age and, finally, 10 years after the initial report
from Marelli et al. (1), to the clinic. In this issue of the
Journal, Menasche´ et al. (14) describe the outcome of the
first clinical trial using skeletal myoblasts for infarct repair.
For those readers who have not followed this field closely, it
should be mentioned that the Dr. Menasche´’s group is
well-established in the cellular cardiomyoplasty field, having
published numerous significant studies in preclinical models
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of infarct repair. For example, they were the first to directly
compare the beneficial effects of cardiomyocyte versus skel-
etal myoblast grafting in a rat infarct model, finding that
skeletal myoblasts were just as effective as fetal cardiomyo-
cytes for improving postinfarction left ventricular (LV)
function (15). Subsequently, they found a significant linear
relationship between the improvement in ejection fraction
and the number of injected skeletal myoblasts after trans-
plantation. They concluded that autologous myoblast trans-
plantation is functionally effective over a wide range of
postinfarct ejection fractions, including the sickest hearts,
provided that they are injected with a sufficiently high
number of cells (16). Most importantly, in 2001 they
reported the first human case study where they implanted
autologous skeletal myoblasts into the postinfarction scar
during coronary artery bypass grafting (CABG) of remote
myocardial areas. Five months after implantation, there was
evidence of contraction and viability in the grafted scar by
echocardiography and positron emission tomography. Al-
though encouraging, the authors were cautious enough to
emphasize the need for validation by additional studies (17).
With the history of this laboratory in mind, the current
phase I trial seems a logical extension of this systematic
approach.
Overview of the phase I trial. Based on the promise of the
preclinical studies and the single case report, Menasche´ et
al. (14) provide a much-awaited clinical follow-up. They
describe the first phase I clinical trial looking at the
feasibility and safety of autologous skeletal myoblast trans-
plantation in patients with severe ischemic cardiomyopathy.
Ten heart failure patients were selected on the basis of: 1)
having an old MI, and 2) needing CABG in areas remote
from the previous infarct. These patients underwent skeletal
muscle biopsy from the thigh, and myoblasts were isolated
from the biopsies for direct injection into infarcted myocar-
dium during bypass surgery. The infarcted regions were
determined as areas that lacked response to low-dose
dobutamine and had 18fluoro-2-deoxyglucose uptake of
50% that of control myocardium by positron emission
tomography imaging. All patients underwent pre- and
postprocedural echocardiographic analysis for LV function.
Because this is a phase I trial, the primary end points were
feasibility and safety of the procedure, and the secondary
end point was efficacy, which was measured primarily as
echocardiographic improvement of the injected sites.
Is skeletal myoblast grafting feasible and safe? Human
myocardium contains 20 million cardiomyocytes per g. If
an LV weighs250 g, and a failure-inducing infarct kills off
30% to 40% of the ventricle, this translates to a deficiency of
750 million to 1 billion cardiomyocytes. Thus, the first goal
was to determine if a physiologically significant number of
skeletal myoblasts could be generated from biopsies in a
timely fashion. The authors report that autologous skeletal
myoblast grafting is, indeed, quite feasible. They set goals of
achieving at least 500 million cells, with a purity of at least
60% myoblasts, within two to three weeks of biopsy. They
easily reached (and generally overshot) these goals, and cell
viability was excellent. Hearts received an average of 37
injections under cardioplegic arrest, delivering an average of
871 million cells in 5.7 ml to a mean area of 29 cm2.
Menasche´ et al. (14) point out that the optimal cell number
for injection is still unknown, but based on their animal data
(16), they have demonstrated that cell number correlates
well with cardiac functional improvement. It is clear that
dose-escalation studies will be required to define the optimal
cell dose for human myoblast grafting.
For any new clinical intervention, safety is obviously of
paramount importance. One of the 10 patients died acutely
from complications unrelated to myoblast injection. Of the
remaining nine patients, four developed monomorphic ven-
tricular tachycardia, one of which included a syncopal event.
These four patients eventually required placement of auto-
matic implantable cardioverter-defibrillator. As of this writ-
ing, one of the four patients has received two appropriate
shocks, while the other three patients have not required
intervention. Were these arrhythmias related to myoblast
implantation? The small size of this trial and the absence of
a control group preclude a definitive answer. The authors,
however, are appropriately cautious about this complication,
stating that the possibility of a direct connection must be
explored further. Their current protocol involves prophylac-
tic administration of amiodarone for three months postop-
eratively. The possible complication of arrhythmias raises
additional questions. Will all patients require a defibrillator
and antiarrhythmic therapy? What would be the added cost?
Additional studies and longer follow-up need to be per-
formed to determine whether there is a significantly higher
risk of developing ventricular arrhythmias after this inter-
vention.
Is skeletal myoblast grafting effective? Menasche´ et al.
(14) stress that this was a feasibility and safety study, neither
designed nor powered to test efficacy. Furthermore, they
emphasize that the concomitant CABG is a variable that
could confound interpretation of functional data. With
these limitations in mind, they attempted a careful assess-
ment of cardiac performance. Left ventricular ejection
fraction significantly improved from 23.8% to 32.1% and
New York Heart Association (NYHA) functional class
from 2.7 to 1.6. These findings are consistent with preclin-
ical animal data on cell transplantation, but also could be
explained by revascularization therapy. To examine effects of
grafting more directly, they examined segmental wall mo-
tion by echocardiography. By correlating the intraoperative
diagrams of cell implantation with echocardiograms, they
estimated that a total of 22 myocardial segments received
myoblast implants. Of these, 14 segments (from six of eight
patients) demonstrated significant improvement in systolic
motion when preoperative and postoperative studies were
compared in a blinded fashion. Menasche´ et al. (14) point
out the limitations of using echocardiography as a measure
for cardiac functional improvement because there is no way
to discriminate whether improvement is a result of passive
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motion from nearby segments enhanced by surgical revas-
cularization alone or, alternatively, through increased col-
lateral flow to the infarcted region. However, they injected
the cells in scarred areas and point out that the observed
improvement is out of proportion to what is expected with
surgical revascularization alone. Thus, they provide tanta-
lizing evidence that myoblast grafts are improving ventric-
ular function. The mechanism for such a functional im-
provement with cell injection still remains a paradox,
especially because differentiated skeletal muscle fibers lack
gap junctions in vivo to allow for synchronized, mechanical
coupling with cardiomyocytes (11). It would be helpful to
know to what extent the 18FDG uptake improved with cell
injection and whether all of the successfully injected regions
also had functional improvement. In addition, it would be
interesting to determine whether functional and NYHA
class improvement are associated with any change in max-
imal exercise capacity and maximal oxygen consumption
during exercise.
Summary and future directions. This trial is a significant
step forward in the area of cell transplantation. We com-
mend the authors for their careful approach to developing
this therapy and for the thoughtful, self-critical analysis that
they have provided. As the first application of cell-based,
regenerative medicine to human heart disease, this study
sets a standard for how cell-based therapies can be moved
safely to the clinic. This trial was based on many dedicated
years of research that first showed promise in rodents and
then was scaled up to larger animals. The authors did not
rush to clinical trials, but rather worked to establish impor-
tant proofs of principle in relevant preclinical models. We
hope that other investigators working in cell-based thera-
peutics will take a similarly reasoned approach. This phase I
trial has opened our eyes to the possibility of arrhythmic
complications and raises the possibility of functional improve-
ment. The stage is now set for placebo-controlled, multicen-
tered trials that will more definitively assess the safety and
efficacy of myoblast transplantation for infarct repair.
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